Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
US Judge Dismisses Gautam Adani Criminal Charges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
3 clinical-grade skincare creams you really shouldn’t buy online 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Patients who lost weight with Eli Lilly's weight-loss drug, Zepbound, eventually regained a significant amount of weight after discontinuing the treatment. These findings were published in the journal JAMA. Shed light on the challenges faced by individuals seeking long-term weight management solutions.
Weight Regain Among Obese Patients
Reuters reported that the study showed that patients with obesity and no diabetes experienced a 14% weight regain nearly a year after transitioning from an eight-month course of Zepbound to a placebo. However, patients who continued the treatment witnessed an additional 5.5% reduction in weight during the 52 weeks.
Sold under the brand name Zepbound for weight loss and known as Mounjaro for type 2 diabetes, Lilly's tirzepatide has emerged as a viable option for individuals struggling with weight management. Tirzepatide, along with Novo Nordisk's Wegovy and Ozempic, belongs to a class of obesity and weight loss treatments that target the GLP-1 hormone.
Risks of Discontinuing Weight-Loss Drugs
Patients who discontinue the use of weight-loss drugs, such as Wegovy, risk regaining their original body weight within approximately five years, as per Bloomberg. Individuals must consider extended therapy with GLP-1 drugs to maximize the long-term benefits of such treatments.
Analysts have underscored the need for extended data evaluation to assess the effects of tirzepatide and other incretin-based therapies after multiple years of continuous treatment. It is essential to gain insights into potential rapidly diminishing responses to these drugs, ensuring better understanding and managing patient weight.
Throughout the 88-week treatment period, patients who continued taking Lilly's drug showcased an impressive 25.3% reduction in weight. In contrast, patients who switched to a placebo after 56 weeks experienced an overall weight reduction of 9.9% during the entire study period.
GLP-1 receptor agonists, including those offered by Novo Nordisk and Eli Lilly, have demonstrated efficacy in inducing a feeling of fullness after eating and slowing gastric emptying. These drugs present a promising approach to address the challenges individuals face in striving for effective weight management.
Photo: Towfiqu barbhuiya/Unsplash
